WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :

Download Article: Click Here

Search

Track Your Article

Abstract

EFFICACY OF TELMISARTAN IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME

Shamna Haris*, Sowparnika Treasa Sabu and Prof (Dr.) Shaiju S. Dharan

Abstract

Background: Metabolic syndrome is a cluster of conditions that occur together which includes elevated blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. This results in an increase in the risk of Heart disease, Stroke and Type II Diabetes Mellitus. Telmisartan, an Angiotensin II receptor blocker (ARB) is found to have efficacy both in lowering Blood pressure and ameliorating metabolic syndrome in hypertensive patients mainly by its peroxisome proliferator-activated receptor (PPARγ) activity which has efficient actions on glucose and fatty acid metabolism. Methods: Previously published articles regarding the efficacy of telmisartan in ameliorating symptoms of metabolic syndrome in addition to efficient control of hypertension by PPAR γ activation. Observations: Telmisartan was found to be effective in partial activation of PPARγ that helps in controlling and improving the symptoms of metabolic syndrome which includes diabetes mellitus, dyslipidemia, obesity etc. Telmisartan showed improvement in insulin resistance by enhancing the expression of GLUT4, down regulating PEPCK and also by augmenting adiponectin production by the adipose cells which helped in increasing insulin sensitivity. It also helped in controlling dyslipidemia by inducing ABCA1/ABCG1 expression and suppressing MCP1 expression and macrophage proliferation by activating PPAR-Gamma which helped in providing anti-atherogenic action.

Keywords: Telmisartan, Metabolic syndrome, PPAR?, Insulin resistance.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More